Who are Rh-endostatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Endostar continuous intravenous infusion, Endostar routine intravenous infusion, recombinant human endostatin, endostar+chemoradiotherapy, Ramucirumab+ paclitaxel, bevacizumab plus chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rh-endostatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Rh-endostatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rh-endostatin (Rh-endostatin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiogenesis inhibitor. Area: Oncology.

phase 3 Angiogenesis inhibitor VEGF signaling pathway; endothelial cells Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Rh-endostatin (Rh-endostatin) — Guangzhou Institute of Respiratory Disease. Rh-endostatin inhibits angiogenesis by blocking new blood vessel formation, thereby starving tumors of their blood supply.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Rh-endostatin TARGET	Rh-endostatin	Guangzhou Institute of Respiratory Disease	phase 3	Angiogenesis inhibitor	VEGF signaling pathway; endothelial cells
Endostar continuous intravenous infusion	Endostar continuous intravenous infusion	Jiangsu Simcere Pharmaceutical Co., Ltd.	phase 3	Angiogenesis inhibitor	VEGF signaling pathway; endothelial cells
Endostar routine intravenous infusion	Endostar routine intravenous infusion	Jiangsu Simcere Pharmaceutical Co., Ltd.	phase 3	Angiogenesis inhibitor	VEGF signaling pathway; endothelial cells
recombinant human endostatin	recombinant human endostatin	Peking University Cancer Hospital & Institute	marketed	Angiogenesis inhibitor	Endothelial cells (multiple pathways including integrin and VEGF-related mechanisms)
endostar+chemoradiotherapy	endostar+chemoradiotherapy	Second Affiliated Hospital of Xi'an Jiaotong University	marketed	Angiogenesis inhibitor	Endothelial cells; inhibits multiple angiogenic pathways
Ramucirumab+ paclitaxel	Ramucirumab+ paclitaxel	AstraZeneca	phase 3	Angiogenesis inhibitor, Microtubule inhibitor	VEGFR2
bevacizumab plus chemotherapy	bevacizumab plus chemotherapy	Liaoning Cancer Hospital & Institute	phase 3	Angiogenesis inhibitor	VEGF-A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiogenesis inhibitor class)

Jiangsu Simcere Pharmaceutical Co., Ltd. · 3 drugs in this class
Eli Lilly and Company · 1 drug in this class
Guangzhou Institute of Respiratory Disease · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Liaoning Cancer Hospital & Institute · 1 drug in this class
PPD Development, LP · 1 drug in this class
Peking University Cancer Hospital & Institute · 1 drug in this class
Sanofi · 1 drug in this class
ARCAGY/ GINECO GROUP · 1 drug in this class
Second Affiliated Hospital of Xi'an Jiaotong University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rh-endostatin — Competitive Intelligence Brief. https://druglandscape.com/ci/rh-endostatin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing